184 related articles for article (PubMed ID: 29069748)
1. Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer.
Tsuji T; Sakamori Y; Ozasa H; Yagi Y; Ajimizu H; Yasuda Y; Funazo T; Nomizo T; Yoshida H; Nagai H; Maeno K; Oguri T; Hirai T; Kim YH
Oncotarget; 2017 Sep; 8(42):71805-71816. PubMed ID: 29069748
[TBL] [Abstract][Full Text] [Related]
2. High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients.
Cañadas I; Taus A; González I; Villanueva X; Gimeno J; Pijuan L; Dómine M; Sánchez-Font A; Vollmer I; Menéndez S; Arpí O; Mojal S; Rojo F; Rovira A; Albanell J; Arriola E
Oncotarget; 2014 Jul; 5(14):5246-56. PubMed ID: 25026301
[TBL] [Abstract][Full Text] [Related]
3. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
4. Prognostic relevance of longitudinal HGF levels in serum of patients with ovarian cancer.
Klotz DM; Link T; Wimberger P; Kuhlmann JD
Mol Oncol; 2021 Dec; 15(12):3626-3638. PubMed ID: 33738970
[TBL] [Abstract][Full Text] [Related]
5. Plasma Biomarkers Screening by Multiplex ELISA Assay in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Costantini A; Takam Kamga P; Julie C; Corjon A; Dumenil C; Dumoulin J; Ouaknine J; Giraud V; Chinet T; Rottman M; Emile JF; Giroux Leprieur E
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396187
[TBL] [Abstract][Full Text] [Related]
6. Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial.
Arrieta O; Cruz-Rico G; Soto-Perez-de-Celis E; Ramírez-Tirado LA; Caballe-Perez E; Martínez-Hernández JN; Martinez-Alvarez I; Soca-Chafre G; Macedo-Pérez EO; Astudillo-de la Vega H
Target Oncol; 2016 Oct; 11(5):619-629. PubMed ID: 27033062
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
Front Immunol; 2020; 11():1173. PubMed ID: 32587591
[No Abstract] [Full Text] [Related]
8. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
9. Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC.
Ying HQ; Liao YC; Luo YR; Xiong G; Huang Y; Nie RW; Xiong CF; Cheng XX
Pharmacol Res; 2021 Aug; 170():105734. PubMed ID: 34157424
[TBL] [Abstract][Full Text] [Related]
10. Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
Tarhini AA; Rafique I; Floros T; Tran P; Gooding WE; Villaruz LC; Burns TF; Friedland DM; Petro DP; Farooqui M; Gomez-Garcia J; Gaither-Davis A; Dacic S; Argiris A; Socinski MA; Stabile LP; Siegfried JM
Cancer; 2017 Aug; 123(15):2936-2944. PubMed ID: 28472537
[TBL] [Abstract][Full Text] [Related]
11. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
12. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
13. Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.
Cui S; Zhao Y; Dong L; Gu A; Xiong L; Qian J; Zhang W; Niu Y; Pan F; Jiang L
Cancer Med; 2016 Jun; 5(6):1013-21. PubMed ID: 26880708
[TBL] [Abstract][Full Text] [Related]
14. Monitoring early dynamic changes of plasma cell-free DNA and pretreatment pre-albumin to predict chemotherapy effectiveness and survival outcomes in advanced non-small cell lung cancer.
Chen J; Shao J; Zhang X; Wei S; Cai H; Wang G
Ann Transl Med; 2022 Mar; 10(5):253. PubMed ID: 35402598
[TBL] [Abstract][Full Text] [Related]
15. Soluble hepatocyte growth factor (sHGF) and vascular endothelial growth factor (sVEGF) in adult acute myeloid leukemia: relationship to disease characteristics.
Aref S; Mabed M; Sakrana M; Goda T; El-Sherbiny M
Hematology; 2002 Oct; 7(5):273-9. PubMed ID: 12850814
[TBL] [Abstract][Full Text] [Related]
16. Gustave Roussy Immune Score Is a Prognostic Factor for Chemotherapy-Naive Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor Receptor.
Minami S; Ihara S; Komuta K
World J Oncol; 2019 Feb; 10(1):55-61. PubMed ID: 30834052
[TBL] [Abstract][Full Text] [Related]
17. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
18. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib.
Azuma K; Hirashima T; Yamamoto N; Okamoto I; Takahashi T; Nishio M; Hirata T; Kubota K; Kasahara K; Hida T; Yoshioka H; Nakanishi K; Akinaga S; Nishio K; Mitsudomi T; Nakagawa K
ESMO Open; 2016; 1(4):e000063. PubMed ID: 27843623
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of plasma coagulation parameters in patients with advanced-stage non-small cell lung cancer treated with palliative chemotherapy in China.
Abbas M; Kassim SA; Wang ZC; Shi M; Hu Y; Zhu HL
Int J Clin Pract; 2020 Dec; 74(12):e13619. PubMed ID: 32726491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
